Ascendia

  MARKET NEWS

Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
Zealand Pharma Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congenital Hyperinsulinism
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
Denali Therapeutics Announces New Interim Data From Phase 1/2 Study of DNL310 in MPS II (Hunter Syndrome)

  FEATURED EDITORIAL

  COMPANY PROFILE

The Health business of Lubrizol Life Science (LLS Health), in partnership with customers, advances solutions inspiring a healthier life. We specialize in helping clients from idea to execution by offering innovative polymers and excipients, as well as best-in-class contract development and manufacturing services. Our long history of polymer expertise and continued investment in research and manufacturing means we offer you and your customers a smooth and streamlined approach to innovative healthcare solutions. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Zenas BioPharma Announces Strategic License & Collaboration Agreement With Bristol Myers Squibb

Zenas BioPharma Announces Strategic License & Collaboration Agreement With Bristol Myers Squibb

Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases….

SomaLogic Expands Agreement With Novo Nordisk to 2025

SomaLogic Expands Agreement With Novo Nordisk to 2025

Novo Nordisk will extend its use of SomaLogic’s innovative proteomics technologies for research in cardiometabolic and other diseases….

Optibrium Acquires BioPharmics, Expanding its 3D Drug Design & Visualization Offering

Optibrium Acquires BioPharmics, Expanding its 3D Drug Design & Visualization Offering

Optibrium recently announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering. Bringing decades of experience in computational chemistry and biology…..

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio & Adding Commercial Product

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio & Adding Commercial Product

Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …

WHITEPAPER - Improving API Solubility by Salt & Cocrystal Formation

WHITEPAPER - Improving API Solubility by Salt & Cocrystal Formation

Ensuring sufficient solubility is critical to the success of small molecule drugs. An active pharmaceutical ingredient (API) must be absorbed by the body and enter the systemic circulation to deliver the desired therapeutic effect. Many APIs, however, suffer from low …

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and skin penetration enhancers.

Considerations include the …

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products

By: Jeffrey Tremain and Ania VanDyke, AbbVie Contract Manufacturing

Regulatory authorities now consider ophthalmic formulations designed for administration as eye drops to be drug-device combination products.The regulatory compliance requirements for such combination products are much more complex than those for

…

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 13 – Bioavailability
September 20 – Capsules